KRRO
Korro Bio, Inc.
NASDAQ · Healthcare · Biotechnology · US
$12.13
+4.39%Year over year
Reported trailing growth
- Revenue
- -62.1%
- EBITDA
- +23.5%
- EBIT
- +23.2%
- EPS
- -2.7%
- Free cash flow
- +7.6%
- Operating cash flow
- -1.0%
Forward estimates
Based on analyst estimates
- Revenue
- -56.3%
- EBITDA
- -12.6%
- EPS
- +53.3%
Three-year CAGR
- Revenue
- +181.5%
- EBITDA
- +6.0%
- EBIT
- +5.0%
- Net income
- -40.3%
- EPS
- -33.2%
- Free cash flow
- -1.4%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026